Balance Sheet StrengthFDC's low leverage and high equity ratio provide durable financial flexibility, reducing refinancing risk and supporting investment, R&D or acquisitions. A conservative balance sheet cushions cyclical pharma revenue swings and underpins long-term strategic optionality.

Cash GenerationMaterial improvement in free cash flow and a favorable operating cash flow to net income ratio indicate sustainable internal funding for capex, working capital and shareholder returns. Reliable cash conversion supports long-term operations and strategic investments.

Revenue & Margin StabilityAn 8.9% revenue increase and stable gross plus stable EBIT/EBITDA margins point to durable commercial execution and cost control. Steady top-line expansion with maintained unit economics supports sustainable profitability and competitive positioning in specialty/generics.

Bears Say

Earnings PressureA ~21% decline in EPS signals material earnings pressure that can reflect margin squeeze, higher expenses or one-off hits. Persisting EPS falls would erode reinvestment capacity and could limit financing flexibility and dividends over a multi-quarter horizon.

Weak Revenue TrendReported revenue growth is slightly negative (~-1.1%), indicating stagnation versus peers. Prolonged flat or contracting top line undermines scale advantages, caps margin expansion potential, and raises questions about sustained market share or demand in key segments.

Margin & FCF Conversion ConcernsA slip in net profit margin combined with suboptimal free cash flow conversion implies earnings are not fully translating to spendable cash. This can constrain funding for growth programs, weaken resilience to pricing pressures, and reduce long-term financial optionality.

FDC Ltd. News

FDC Gets USFDA ANDA Nod for Fluconazole Tablets

FDC Ltd. ( ($IN:FDC) ) has provided an update. FDC Ltd. has received approval from the U.S. Food...

2M ago

FDC

FDC Limited Confirms Compliance with SEBI Regulations for Q3 2025

FDC Ltd. ( ($IN:FDC) ) has shared an update. FDC Limited has submitted a certificate to the stock...

5M ago

FDC

FDC FAQ

What was FDC Ltd.’s price range in the past 12 months?

FDC Ltd. lowest stock price was ₹330.05 and its highest was ₹528.30 in the past 12 months.

What is FDC Ltd.’s market cap?

FDC Ltd.’s market cap is ₹60.38B.

When is FDC Ltd.’s upcoming earnings report date?

FDC Ltd.’s upcoming earnings report date is May 27, 2026 which is in 83 days.

How were FDC Ltd.’s earnings last quarter?

FDC Ltd. released its earnings results on Feb 05, 2026. The company reported ₹1.738 earnings per share for the quarter, beating the consensus estimate of N/A by ₹1.738.

Is FDC Ltd. overvalued?

According to Wall Street analysts FDC Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does FDC Ltd. pay dividends?

FDC Ltd. pays a Notavailable dividend of ₹5 which represents an annual dividend yield of 1.22%. See more information on FDC Ltd. dividends here

What is FDC Ltd.’s EPS estimate?

FDC Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does FDC Ltd. have?

FDC Ltd. has 162,810,090 shares outstanding.

What happened to FDC Ltd.’s price movement after its last earnings report?

FDC Ltd. reported an EPS of ₹1.738 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -2.606%.

Which hedge fund is a major shareholder of FDC Ltd.?

Currently, no hedge funds are holding shares in IN:FDC

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

FDC Ltd.

FDC Limited manufactures and markets pharmaceutical products in India and internationally. The company offers specialized formulations for various therapeutic segments, including anti-infective, gastrointestinal, ophthalmological, vitamins/minerals/dietary supplements, cardiac, anti-diabetes, respiratory, gynecology, dermatology, analgesics, and others; and oral rehydration salts. It provides specialized formulations primarily under the Zifi, Electral, Enerzal, Vitcofol, Pyrimon, Zocon, Zoxan, Zathrin, Zipod, Zefu, Cotaryl, and Mycoderm brand names. The company also offers anti-oxidants, balanced energy drinks, and vitamins and nutraceuticals under the Enerzal, Humyl, Mum Mum 1, Prosoyal, Simyl-LBW, Simyl-MCT, and Zefrich brands. In addition, it provides various active pharmaceutical ingredients. FDC Limited was founded in 1936 and is headquartered in Mumbai, India.